Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LNP023 - Factor B inhibition of the complement alternative pathway Study Indication Phase Patients Primary Outcome Measures NCT03955445 (CLNP023B12001B) C3 glomerulopathy (C3G) Phase 2 27 Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Arms Intervention Open-label LNP023 200mg bid NCT04154787 (CLNP023D12201) Idiopathic membranous nephropathy (IMN) Phase 2 72 Change from baseline of UPCR derived from 24hr urine collections at Baseline and Week 24 LNP023 low dose LNP023 high dose Rituximab Patients with biopsy proven iMN who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria 2023 Target Patients Patients with C3 glomerulopathy Read-out Milesstone(s) Publication 2025 Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory TBD 66 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation